Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma

The monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2 (CLDN18.2), a GC biomarker. This study aimed to determine the prevalence of CLDN18.2 in primary tumors and lymph node (LN) metastases of Japanese p...

Full description

Saved in:

Bibliographic Details
Published in:	Japanese journal of clinical oncology Vol. 49; no. 9; p. 870
Main Authors:	Rohde, Christoph, Yamaguchi, Rin, Mukhina, Svetlana, Sahin, Ugur, Itoh, Kyogo, Türeci, Özlem
Format:	Journal Article
Language:	English
Published:	England 01.09.2019
Subjects:	Adenocarcinoma - genetics Adenocarcinoma - metabolism Adenocarcinoma - pathology Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asian Continental Ancestry Group Claudins - genetics Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Lymphatic Metastasis - genetics Stomach Neoplasms - genetics Stomach Neoplasms - metabolism Stomach Neoplasms - pathology prevalence immunohistochemistry gastric cancer Claudin biomarkers
ISSN:	1465-3621, 1465-3621
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	The monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2 (CLDN18.2), a GC biomarker. This study aimed to determine the prevalence of CLDN18.2 in primary tumors and lymph node (LN) metastases of Japanese patients with GC. CLDN18.2 expression was investigated in tissue samples from patients with gastric adenocarcinoma archived at Kurume University Medical Center, Japan, between 2000 and 2012. Expression of CLDN18.2 in tumor samples was evaluated by immunohistochemistry using the same detection antibody (43-14A) and assay used in the FAST clinical trial (NCT01630083), a phase 2 randomized trial that compared the safety and antitumor activity of the zolbetuximab-chemotherapy combination with chemotherapy alone. Samples showing any specific staining with ≥1+ intensity were defined as CLDN18.2-positive. Of 263 samples analyzed (134 primary gastric tumors and corresponding LN metastases; 128 primary tumors only; one LN metastases only), CLDN18.2 was detected in 87% (n = 228/262) of all primary tumors and 80% (n = 108/135) of LN metastases. Moderate-to-strong CLDN18.2 expression (≥2+ membrane staining intensity in ≥40% of tumor cells [FAST eligibility criterion]) was observed in 52% (n = 135/262) of primary tumors and 45% (n = 61/135) of (LN) metastases. CLDN18.2 expression was significantly higher in GCs of the diffuse histological subtype per Lauren classification and in high grade (G3) tumors. The high prevalence of CLDN18.2 among Japanese patients with GC supports the therapeutic assessment of zolbetuximab in this population.
AbstractList	The monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2 (CLDN18.2), a GC biomarker. This study aimed to determine the prevalence of CLDN18.2 in primary tumors and lymph node (LN) metastases of Japanese patients with GC. CLDN18.2 expression was investigated in tissue samples from patients with gastric adenocarcinoma archived at Kurume University Medical Center, Japan, between 2000 and 2012. Expression of CLDN18.2 in tumor samples was evaluated by immunohistochemistry using the same detection antibody (43-14A) and assay used in the FAST clinical trial (NCT01630083), a phase 2 randomized trial that compared the safety and antitumor activity of the zolbetuximab-chemotherapy combination with chemotherapy alone. Samples showing any specific staining with ≥1+ intensity were defined as CLDN18.2-positive. Of 263 samples analyzed (134 primary gastric tumors and corresponding LN metastases; 128 primary tumors only; one LN metastases only), CLDN18.2 was detected in 87% (n = 228/262) of all primary tumors and 80% (n = 108/135) of LN metastases. Moderate-to-strong CLDN18.2 expression (≥2+ membrane staining intensity in ≥40% of tumor cells [FAST eligibility criterion]) was observed in 52% (n = 135/262) of primary tumors and 45% (n = 61/135) of (LN) metastases. CLDN18.2 expression was significantly higher in GCs of the diffuse histological subtype per Lauren classification and in high grade (G3) tumors. The high prevalence of CLDN18.2 among Japanese patients with GC supports the therapeutic assessment of zolbetuximab in this population. The monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2 (CLDN18.2), a GC biomarker. This study aimed to determine the prevalence of CLDN18.2 in primary tumors and lymph node (LN) metastases of Japanese patients with GC.BACKGROUNDThe monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2 (CLDN18.2), a GC biomarker. This study aimed to determine the prevalence of CLDN18.2 in primary tumors and lymph node (LN) metastases of Japanese patients with GC.CLDN18.2 expression was investigated in tissue samples from patients with gastric adenocarcinoma archived at Kurume University Medical Center, Japan, between 2000 and 2012. Expression of CLDN18.2 in tumor samples was evaluated by immunohistochemistry using the same detection antibody (43-14A) and assay used in the FAST clinical trial (NCT01630083), a phase 2 randomized trial that compared the safety and antitumor activity of the zolbetuximab-chemotherapy combination with chemotherapy alone. Samples showing any specific staining with ≥1+ intensity were defined as CLDN18.2-positive.METHODSCLDN18.2 expression was investigated in tissue samples from patients with gastric adenocarcinoma archived at Kurume University Medical Center, Japan, between 2000 and 2012. Expression of CLDN18.2 in tumor samples was evaluated by immunohistochemistry using the same detection antibody (43-14A) and assay used in the FAST clinical trial (NCT01630083), a phase 2 randomized trial that compared the safety and antitumor activity of the zolbetuximab-chemotherapy combination with chemotherapy alone. Samples showing any specific staining with ≥1+ intensity were defined as CLDN18.2-positive.Of 263 samples analyzed (134 primary gastric tumors and corresponding LN metastases; 128 primary tumors only; one LN metastases only), CLDN18.2 was detected in 87% (n = 228/262) of all primary tumors and 80% (n = 108/135) of LN metastases. Moderate-to-strong CLDN18.2 expression (≥2+ membrane staining intensity in ≥40% of tumor cells [FAST eligibility criterion]) was observed in 52% (n = 135/262) of primary tumors and 45% (n = 61/135) of (LN) metastases. CLDN18.2 expression was significantly higher in GCs of the diffuse histological subtype per Lauren classification and in high grade (G3) tumors.RESULTSOf 263 samples analyzed (134 primary gastric tumors and corresponding LN metastases; 128 primary tumors only; one LN metastases only), CLDN18.2 was detected in 87% (n = 228/262) of all primary tumors and 80% (n = 108/135) of LN metastases. Moderate-to-strong CLDN18.2 expression (≥2+ membrane staining intensity in ≥40% of tumor cells [FAST eligibility criterion]) was observed in 52% (n = 135/262) of primary tumors and 45% (n = 61/135) of (LN) metastases. CLDN18.2 expression was significantly higher in GCs of the diffuse histological subtype per Lauren classification and in high grade (G3) tumors.The high prevalence of CLDN18.2 among Japanese patients with GC supports the therapeutic assessment of zolbetuximab in this population.CONCLUSIONSThe high prevalence of CLDN18.2 among Japanese patients with GC supports the therapeutic assessment of zolbetuximab in this population.
Author	Sahin, Ugur Itoh, Kyogo Rohde, Christoph Türeci, Özlem Yamaguchi, Rin Mukhina, Svetlana
Author_xml	– sequence: 1 givenname: Christoph surname: Rohde fullname: Rohde, Christoph organization: Formerly of Ganymed Pharmaceuticals GmbH, Mainz, Germany – sequence: 2 givenname: Rin surname: Yamaguchi fullname: Yamaguchi, Rin organization: Department of Pathology and Clinical Medicine, Kurume University Medical Center, Kurume, Fukuoka, Japan – sequence: 3 givenname: Svetlana surname: Mukhina fullname: Mukhina, Svetlana organization: Formerly of Ganymed Pharmaceuticals GmbH, Mainz, Germany – sequence: 4 givenname: Ugur surname: Sahin fullname: Sahin, Ugur organization: TRON, Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany – sequence: 5 givenname: Kyogo surname: Itoh fullname: Itoh, Kyogo organization: Kurume University Cancer Vaccine Center, Kurume, Fukuoka, Japan – sequence: 6 givenname: Özlem surname: Türeci fullname: Türeci, Özlem organization: Ci3-Cluster of Individualized Immune Intervention, Mainz, Germany
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31087075$$D View this record in MEDLINE/PubMed
BookMark	eNpNkM1LxDAQxYOsuB968i45eumapE2bHqX4yYIXPZdpO3WzNElNWnQ9-pdbcQXhwQxvfgwzb0lm1lkk5JyzNWd5fLXb1e5qu_9kqToiC56kMopTwWf_-jlZhrBjjEmVZCdkHnOmMpbJBfkqnOnB6-AsdS0tOhgbbSlXa0Hxo_cYgp5Gk9V7bcDv6TAa5wMF29Bub_otta5BanCAMAnDD_sIPVgMSHsYNNoh0Hc9bOnrhHhdU2jQuhp8ra0zcEqOW-gCnh3qirzc3jwX99Hm6e6huN5EdcLkEOXIFUol2jzjmMkcVA5JrColVCXithKSp3mVpk2sJM9Atk2OrWobTBVADbFYkcvfvb13byOGoTQ61Nh106luDKUQsWAsSfJsQi8O6FgZbMrD7-VfbuIbaV9zow
CitedBy_id	crossref_primary_10_3390_cancers16030679 crossref_primary_10_1016_j_prp_2022_154068 crossref_primary_10_1186_s13045_023_01451_3 crossref_primary_10_1007_s00428_025_04081_x crossref_primary_10_1080_21688370_2025_2535047 crossref_primary_10_3390_cancers13225660 crossref_primary_10_47493_abantmedj_1313791 crossref_primary_10_1158_2326_6066_CIR_24_0138 crossref_primary_10_1007_s12094_020_02380_0 crossref_primary_10_3389_fonc_2025_1596460 crossref_primary_10_1038_s41591_025_03781_w crossref_primary_10_1111_his_14358 crossref_primary_10_1002_hsr2_2261 crossref_primary_10_3390_biomedicines10030543 crossref_primary_10_1016_j_prp_2024_155628 crossref_primary_10_3389_fonc_2020_01214 crossref_primary_10_3389_fonc_2022_889017 crossref_primary_10_1007_s10120_024_01518_1 crossref_primary_10_5230_jgc_2025_25_e2 crossref_primary_10_1080_21688370_2021_1967080 crossref_primary_10_1007_s12254_023_00944_8 crossref_primary_10_1016_j_modpat_2025_100712 crossref_primary_10_3390_medsci10010004 crossref_primary_10_1007_s10147_024_02525_z crossref_primary_10_1016_j_isci_2025_113491 crossref_primary_10_1007_s10330_020_0470_0 crossref_primary_10_1186_s12885_023_10533_x crossref_primary_10_1097_PAI_0000000000000971 crossref_primary_10_3389_fonc_2021_643872 crossref_primary_10_3390_cancers17060998 crossref_primary_10_1111_cas_15684 crossref_primary_10_1016_j_modpat_2024_100589 crossref_primary_10_1186_s12885_024_11980_w crossref_primary_10_4251_wjgo_v15_i2_343 crossref_primary_10_1016_j_clon_2024_04_013 crossref_primary_10_1016_j_esmogo_2025_100210 crossref_primary_10_1007_s11523_024_01097_2 crossref_primary_10_3390_cancers17071120 crossref_primary_10_1007_s10120_024_01505_6 crossref_primary_10_1016_j_heliyon_2024_e34611 crossref_primary_10_3389_fonc_2024_1454882 crossref_primary_10_1038_s41598_024_68411_w crossref_primary_10_1136_jcp_2024_209914 crossref_primary_10_3389_fonc_2023_1258347 crossref_primary_10_1016_j_modpat_2024_100569 crossref_primary_10_1126_science_aay5967 crossref_primary_10_2147_ITT_S494696 crossref_primary_10_1007_s00259_022_05739_3 crossref_primary_10_1016_j_modpat_2025_100844 crossref_primary_10_1177_17588359231217967 crossref_primary_10_1007_s40618_023_02245_7 crossref_primary_10_1111_pin_13349 crossref_primary_10_1186_s43088_023_00449_7 crossref_primary_10_1007_s13402_025_01066_5 crossref_primary_10_3390_jpm11111095 crossref_primary_10_1186_s12876_023_02924_y crossref_primary_10_1007_s10620_024_08435_4 crossref_primary_10_2147_JIR_S368138 crossref_primary_10_3390_cancers17121996 crossref_primary_10_1155_2020_4258035 crossref_primary_10_3390_cancers17030340 crossref_primary_10_1016_j_labinv_2023_100284 crossref_primary_10_1016_j_critrevonc_2025_104941 crossref_primary_10_1159_000547239 crossref_primary_10_1186_s12885_025_13940_4 crossref_primary_10_1007_s10120_024_01573_8 crossref_primary_10_1038_s41591_023_02465_7 crossref_primary_10_1007_s00428_019_02624_7 crossref_primary_10_1186_s12876_023_02843_y crossref_primary_10_1093_jjco_hyaa205 crossref_primary_10_3390_antib14010026 crossref_primary_10_3389_fonc_2023_1132319 crossref_primary_10_1089_cbr_2020_4089 crossref_primary_10_1038_s41571_024_00874_2 crossref_primary_10_1186_s40364_022_00385_1 crossref_primary_10_1007_s00432_022_04408_0 crossref_primary_10_1038_s41392_024_02097_4 crossref_primary_10_1016_j_prp_2024_155145 crossref_primary_10_1038_s41598_023_47178_6 crossref_primary_10_1093_oncolo_oyae238 crossref_primary_10_1016_S0140_6736_23_00620_7 crossref_primary_10_1097_PAI_0000000000001248 crossref_primary_10_1097_PAS_0000000000002464 crossref_primary_10_5858_arpa_2021_0428_OA crossref_primary_10_1186_s12916_022_02421_1 crossref_primary_10_3390_cancers14112758 crossref_primary_10_1002_jso_26874 crossref_primary_10_1007_s40262_025_01552_x crossref_primary_10_12677_acm_2025_1582427
ContentType	Journal Article
Copyright	The Author(s) 2019. Published by Oxford University Press.
Copyright_xml	– notice: The Author(s) 2019. Published by Oxford University Press.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/jjco/hyz068
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1465-3621
ExternalDocumentID	31087075
Genre	Randomized Controlled Trial Clinical Trial, Phase II Journal Article
GroupedDBID	--- -E4 .2P .I3 .ZR 0R~ 18M 1TH 29J 2WC 4.4 482 48X 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN M-Z M49 MHKGH ML0 N9A NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y RD5 RHF ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 ABPQP ADNBA AEMQT AHGBF AJBYB AJNCP ALXQX JXSIZ
ID	FETCH-LOGICAL-c405t-9e18e582f971e759a89a438b828b23fb25169b66d38517a5fd9ef8fde68aaca32
IEDL.DBID	7X8
ISICitedReferencesCount	113
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000493070300010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1465-3621
IngestDate	Sat Sep 27 18:46:50 EDT 2025 Wed Feb 19 02:31:51 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	prevalence immunohistochemistry gastric cancer Claudin biomarkers
Language	English
License	The Author(s) 2019. Published by Oxford University Press.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c405t-9e18e582f971e759a89a438b828b23fb25169b66d38517a5fd9ef8fde68aaca32
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC6792344
PMID	31087075
PQID	2232004497
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2232004497 pubmed_primary_31087075
PublicationCentury	2000
PublicationDate	2019-09-01
PublicationDateYYYYMMDD	2019-09-01
PublicationDate_xml	– month: 09 year: 2019 text: 2019-09-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Japanese journal of clinical oncology
PublicationTitleAlternate	Jpn J Clin Oncol
PublicationYear	2019
SSID	ssj0005847
Score	2.5708427
Snippet	The monoclonal antibody zolbetuximab (formerly IMAB362), which is being developed as a potential treatment for gastric cancer (GC), targets Claudin 18.2...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	870
SubjectTerms	Adenocarcinoma - genetics Adenocarcinoma - metabolism Adenocarcinoma - pathology Antibodies, Monoclonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asian Continental Ancestry Group Claudins - genetics Gene Expression Regulation, Neoplastic Humans Immunohistochemistry Lymphatic Metastasis - genetics Stomach Neoplasms - genetics Stomach Neoplasms - metabolism Stomach Neoplasms - pathology
Title	Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
URI	https://www.ncbi.nlm.nih.gov/pubmed/31087075 https://www.proquest.com/docview/2232004497
Volume	49
WOSCitedRecordID	wos000493070300010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JSwMxFA5qRby4L3UjgtfYzprkJFIsIrb0oNJbyaqWdqZ2WrEe_eW-tKk9CYKXOQyT8EjevPe9JfkQujAxuA3BA6K5oCRmVhEuo4QIq2QS2FRXp_RtT_e02WTtNm_5hFvh2yrnNnFqqHWuXI68Am7MbWjM6dXgjTjWKFdd9RQay6gUAZRxWk3bi9vCXQlwdrooIWCoA38-D4L4Srer8srL5LOast-x5dTH1Df_K90W2vDoEl_P1GEbLZlsB601fP18F33VfmgHcW5xrSfG4LtwwC5DbD58T2yG4dVgdgsFHo37-bDAItO4N4Gdx1muDe6bkQBYWZjCfXsHDtcRWWJ_SWuBXXYXPwvHCaKwANMGHnMIIuR9sYce6zcPtVviWRiIAjA3ItwEzCQstJwGhiZcMC7iiEkI1WQYWRm6SptMUx0BeKMisZoby6w2KRNCiSjcRytZnplDhFOWcB0CAlQBTJGGMqap4BAUwaSRDGQZnc9XtwNa7koXIH4-LjqL9S2jg9kWdfxCdACggtGhydEfRh-jdUA8vknsBJUs_OPmFK2q99FrMTybqg88m63GN4VE0ig
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Claudin+18.2+expression+in+primary+tumors+and+lymph+node+metastases+in+Japanese+patients+with+gastric+adenocarcinoma&rft.jtitle=Japanese+journal+of+clinical+oncology&rft.au=Rohde%2C+Christoph&rft.au=Yamaguchi%2C+Rin&rft.au=Mukhina%2C+Svetlana&rft.au=Sahin%2C+Ugur&rft.date=2019-09-01&rft.eissn=1465-3621&rft.volume=49&rft.issue=9&rft.spage=870&rft_id=info:doi/10.1093%2Fjjco%2Fhyz068&rft_id=info%3Apmid%2F31087075&rft_id=info%3Apmid%2F31087075&rft.externalDocID=31087075
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-3621&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-3621&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-3621&client=summon